BACKGROUND: Multidisciplinary predialysis care results in fewer hospitalizations and more patients starting hemodialysis therapy with vascular access. Rigorous comparisons of the effect of different types of predialysis care on outcomes after the initiation of dialysis therapy are in their infancy. We hypothesized that outcomes after the initiation of dialysis therapy would be superior in patients receiving multidisciplinary predialysis care than in those receiving conventional care. METHODS: All incident dialysis patients at our center who had received at least 3 months of specialist predialysis care were categorized according to whether they had attended the multidisciplinary Progressive Renal Disease Clinic (PRDC). Patients with a failed transplant, acute renal failure, or previous renal replacement therapy were excluded. We compared these groups at initiation and during 3 years of dialysis therapy. RESULTS: At the start of dialysis therapy, patient demographics and residual renal function were similar. PRDC patients were more likely to have a functioning access and be administered angiotensin-converting enzyme inhibitors, iron supplements, and bicarbonate therapy and had greater serum albumin and serum calcium levels. PRDC patients had fewer hospitalizations at 1 year (7.0 versus 69.7 d/patient/y; P < 0.01) and during the study duration (10.8 versus 57.4 d/patient/y; P < 0.05). There were fewer deaths in the PRDC group at 1 year (2% versus 23%; P < 0.01) and during the study duration (21% versus 42%; P < 0.05). A history of cardiovascular disease, older age, and non-PRDC predialysis care independently predicted death on dialysis therapy. CONCLUSION: Multidisciplinary predialysis care is associated with superior clinical outcomes after the start of dialysis therapy.
BACKGROUND: Multidisciplinary predialysis care results in fewer hospitalizations and more patients starting hemodialysis therapy with vascular access. Rigorous comparisons of the effect of different types of predialysis care on outcomes after the initiation of dialysis therapy are in their infancy. We hypothesized that outcomes after the initiation of dialysis therapy would be superior in patients receiving multidisciplinary predialysis care than in those receiving conventional care. METHODS: All incident dialysis patients at our center who had received at least 3 months of specialist predialysis care were categorized according to whether they had attended the multidisciplinary Progressive Renal Disease Clinic (PRDC). Patients with a failed transplant, acute renal failure, or previous renal replacement therapy were excluded. We compared these groups at initiation and during 3 years of dialysis therapy. RESULTS: At the start of dialysis therapy, patient demographics and residual renal function were similar. PRDC patients were more likely to have a functioning access and be administered angiotensin-converting enzyme inhibitors, iron supplements, and bicarbonate therapy and had greater serum albumin and serum calcium levels. PRDC patients had fewer hospitalizations at 1 year (7.0 versus 69.7 d/patient/y; P < 0.01) and during the study duration (10.8 versus 57.4 d/patient/y; P < 0.05). There were fewer deaths in the PRDC group at 1 year (2% versus 23%; P < 0.01) and during the study duration (21% versus 42%; P < 0.05). A history of cardiovascular disease, older age, and non-PRDC predialysis care independently predicted death on dialysis therapy. CONCLUSION: Multidisciplinary predialysis care is associated with superior clinical outcomes after the start of dialysis therapy.
Authors: Jeffrey Perl; Ron Wald; Philip McFarlane; Joanne M Bargman; Edward Vonesh; Yingbo Na; S Vanita Jassal; Louise Moist Journal: J Am Soc Nephrol Date: 2011-04-21 Impact factor: 10.121
Authors: Annie-Claire Nadeau-Fredette; Carmel M Hawley; Elaine M Pascoe; Christopher T Chan; Philip A Clayton; Kevan R Polkinghorne; Neil Boudville; Martine Leblanc; David W Johnson Journal: Clin J Am Soc Nephrol Date: 2015-06-11 Impact factor: 8.237
Authors: Brendan J Barrett; Amit X Garg; Ron Goeree; Adeera Levin; Anita Molzahn; Claudio Rigatto; Joel Singer; George Soltys; Steven Soroka; Dieter Ayers; Patrick S Parfrey Journal: Clin J Am Soc Nephrol Date: 2011-05-26 Impact factor: 8.237
Authors: Jeffrey Perl; Jinyao Zhang; Brenda Gillespie; Bjorn Wikström; Joan Fort; Takeshi Hasegawa; Douglas S Fuller; Ronald L Pisoni; Bruce M Robinson; Francesca Tentori Journal: Nephrol Dial Transplant Date: 2012-09-30 Impact factor: 5.992
Authors: Pietro Dattolo; Stefano Michelassi; Marco Amidone; Marco Allinovi; Lorenzo Vignali; Giulia Antognoli; Rosa Roperto; Francesco Pizzarelli Journal: J Nephrol Date: 2014-07-18 Impact factor: 3.902